In Friday’s Wall Street session, CytomX Therapeutics Inc (NASDAQ:CTMX) shares traded at $0.93, down -14.83% from the previous session.
CTMX stock price is now 39.02% away from the 50-day moving average and -4.31% away from the 200-day moving average. The market capitalization of the company currently stands at $74.85M.
On May 28, 2024, Piper Sandler Upgraded its previous ‘Neutral’ rating to ‘Overweight’ on the stock increasing its target price from $2.25 to quote $3.50, while ‘Wedbush’ rates the stock as ‘Outperform’
In other news, McCarthy Sean A., CEO sold 37,656 shares of the company’s stock on Mar 18 ’25. The stock was sold for $22,556 at an average price of $0.60. Upon completion of the transaction, the CEO now directly owns 995,195 shares in the company, valued at $0.93 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 18 ’25, Chief Financial Officer Ogden Christopher sold 8,551 shares of the business’s stock. A total of $5,122 was realized by selling the stock at an average price of $0.60. This leaves the insider owning 201,026 shares of the company worth $0.19 million. A total of 2.46% of the company’s stock is owned by insiders.
During the past 12 months, CytomX Therapeutics Inc has had a low of $0.40 and a high of $2.81.
The company reported revenue of $38.09 million for the quarter, compared to $26.61 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 43.17 percent.
